GlassScriptPhysician profile
Charles C Smith III
NPI 1366493025
$2,571.23
in general payments reported to CMS, 2019-2025
30 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $148 · 2021: $11.90 · 2022: $378 · 2023: $692 · 2024: $432 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $342.35 | 2020-2025 | |
| Amgen INC. | $318.51 | 2019-2025 | Repatha, Repatha, Otezla |
| Genzyme Corporation | $260.31 | 2023-2025 | |
| Glaxosmithkline, LLC. | $208.55 | 2019-2025 | Trelegy Ellipta, Nucala |
| Mylan Specialty L.P. | $177.40 | 2022-2024 | Yupelri |
| Genentech USA, INC. | $117.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $114.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.86 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $95.51 | 2021-2025 | Tezspire, Breztri |
| Novartis Pharmaceuticals Corporation | $93.50 | 2022-2025 | |
| Novo Nordisk INC | $91.50 | 2019-2025 | Ozempic |
| Idorsia Pharmaceuticals US INC | $91.13 | 2022-2024 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $80.21 | 2023-2024 | Dupixent, Evkeeza |
| Sunovion Pharmaceuticals INC. | $47.10 | 2020 | |
| Grifols USA, LLC | $44.59 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $41.86 | 2022 | |
| Dexcom, INC. | $41.06 | 2025 | Dexcom G6 Transmitter |
| Halozyme INC | $35.52 | 2023 | |
| Verona Pharma, INC. | $33.96 | 2025 | Ohtuvayre |
| Pinnacle Biologics, INC | $32.27 | 2025 | Photofrin |
| Antares Pharma, INC. | $31.91 | 2024-2025 | Xyosted |
| Paratek Pharmaceuticals, INC. | $30.00 | 2025 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $26.47 | 2022 | |
| Insmed, INC. | $21.08 | 2025 | Arikayce |
| Lilly USA, LLC | $20.80 | 2024 | Jardiance, Zepbound |
| Radius Health, INC. | $20.72 | 2020 | |
| Cleerly, INC. | $15.64 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Boston Scientific Corporation | $14.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2022 | |
| Electromed, INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Smith III listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.